Raj K. Puri
CIK: 0002046483
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
IOVANCE BIOTHERAPEUTICS, INC.
Discretionary Trading P&L
Holdings
Transaction History (28 total)
- Sep 8, 2026IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Tax Payment(F)Direct4.5K shares at avg. $8.70$39K - Sep 8, 2026IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Exercise(M)Direct9.8K shares- - Sep 1, 2026IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Exercise(M)Direct5.5K shares- - Sep 1, 2026IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Tax Payment(F)Direct2.5K shares at avg. $8.28$21K - Jun 16, 2026IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Award(A)DirectRestricted Stock Units
15K shares- - Jun 5, 2026IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Exercise(M)Direct9.8K shares- - Jun 5, 2026IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Tax Payment(F)Direct3.8K shares at avg. $4.23$16K - Jun 1, 2026IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Tax Payment(F)Direct2.5K shares at avg. $3.96$10K - Jun 1, 2026IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Exercise(M)Direct5.5K shares- - Mar 9, 2026IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Award(A)DirectRestricted Stock Units
117.5K shares- - Mar 5, 2026IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Tax Payment(F)Direct18.4K shares at avg. $4.58$84K - Mar 5, 2026IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Exercise(M)Direct39.1K shares- - Mar 2, 2026IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Tax Payment(F)Direct2.8K shares at avg. $3.79$11K - Mar 2, 2026IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Exercise(M)Direct5.5K shares- - Dec 1, 2025IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Exercise(M)Direct5.5K shares- - Dec 1, 2025IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Tax Payment(F)Direct2.5K shares at avg. $2.23$6K - Sep 2, 2025IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Exercise(M)Direct5.5K shares- - Sep 2, 2025IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Tax Payment(F)Direct2.5K shares at avg. $2.19$5K - Jun 2, 2025IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Exercise(M)Direct5.5K shares- - Jun 2, 2025IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Tax Payment(F)Direct2.5K shares at avg. $1.76$4K - May 23, 2025IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Purchase(P)Direct5.6K shares at avg. $1.74$10K - Mar 14, 2025IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Tax Payment(F)Direct2.5K shares at avg. $3.59$9K - Mar 14, 2025IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Exercise(M)Direct8.3K shares- - Mar 5, 2025IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Award(A)DirectRestricted Stock Units
117.2K shares- - Mar 3, 2025IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Tax Payment(F)Direct20K shares at avg. $4.04$81K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 8, 2026 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Tax Payment(F) | 4,478 | $8.70 | $38,959 | Direct |
| Sep 8, 2026 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Exercise(M) | 9,766 | - | $0 | Direct |
| Sep 1, 2026 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Exercise(M) | 5,470 | - | $0 | Direct |
| Sep 1, 2026 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Tax Payment(F) | 2,508 | $8.28 | $20,766 | Direct |
| Jun 16, 2026 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Award(A) Restricted Stock Units | 15,000 | - | - | Direct |
| Jun 5, 2026 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Exercise(M) | 9,766 | - | $0 | Direct |
| Jun 5, 2026 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Tax Payment(F) | 3,843 | $4.23 | $16,256 | Direct |
| Jun 1, 2026 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Tax Payment(F) | 2,508 | $3.96 | $9,932 | Direct |
| Jun 1, 2026 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Exercise(M) | 5,469 | - | $0 | Direct |
| Mar 9, 2026 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Award(A) Restricted Stock Units | 117,500 | - | - | Direct |
| Mar 5, 2026 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Tax Payment(F) | 18,360 | $4.58 | $84,089 | Direct |
| Mar 5, 2026 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Exercise(M) | 39,059 | - | $0 | Direct |
| Mar 2, 2026 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Tax Payment(F) | 2,798 | $3.79 | $10,604 | Direct |
| Mar 2, 2026 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Exercise(M) | 5,470 | - | $0 | Direct |
| Dec 1, 2025 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Exercise(M) | 5,469 | - | - | Direct |
| Dec 1, 2025 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Tax Payment(F) | 2,467 | $2.23 | $5,501 | Direct |
| Sep 2, 2025 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Exercise(M) | 5,470 | - | - | Direct |
| Sep 2, 2025 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Tax Payment(F) | 2,467 | $2.19 | $5,403 | Direct |
| Jun 2, 2025 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Exercise(M) | 5,469 | - | - | Direct |
| Jun 2, 2025 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Tax Payment(F) | 2,467 | $1.76 | $4,342 | Direct |
| May 23, 2025 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Purchase(P) | 5,600 | $1.74 | $9,743 | Direct |
| Mar 14, 2025 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Tax Payment(F) | 2,509 | $3.59 | $9,007 | Direct |
| Mar 14, 2025 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Exercise(M) | 8,334 | - | - | Direct |
| Mar 5, 2025 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Award(A) Restricted Stock Units | 117,190 | - | - | Direct |
| Mar 3, 2025 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Tax Payment(F) | 19,984 | $4.04 | $80,735 | Direct |
1-25 of 28 transactions
About Puri Raj K.
Puri Raj K. (SEC CIK 0002046483) files insider reports with the SEC as Chief Regulatory Officer of IOVANCE BIOTHERAPEUTICS, INC. (IOVA).
Signal8 holds 17 ownership filings by Puri Raj K. (1 Form 3, 16 Form 4), filed between Dec 2, 2024 and Sep 10, 2026. Those filings report 28 transactions, from Dec 16, 2024 to Sep 8, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Puri Raj K.'s filings is in SAN CARLOS, CA.
Recent filings by Puri Raj K.
- Sep 8, 2026: Tax withholding of IOVA shares (Form 4, code F).
- Sep 8, 2026: Option exercise of IOVA shares (Form 4, code M).
- Sep 1, 2026: Option exercise of IOVA shares (Form 4, code M).
- Sep 1, 2026: Tax withholding of IOVA shares (Form 4, code F).
- Jun 16, 2026: Grant or award of IOVA derivative securities (Form 4, code A).
Other insiders filing for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
- Berkowitz Noah, Chief Medical Officer
- Vogt Frederick G, Interim CEO & General Counsel
- BILINSKY IGOR, Chief Operating Officer
- Kirby Daniel Gordon, Chief Commercial Officer
- Roche Corleen M., Chief Financial Officer
- WEISER MICHAEL, Director